Mandate

Vinge advises Zellis Group, a portfolio company of Apax Partners, in connection with the acquisition of Benify

Vinge has, together with Kirkland & Ellis, advised Zellis Group, a portfolio company of funds advised by Apax Partners LLP (“Apax”), in connection with the acquisition of Benify, a provider of employee benefits administration software, from Vitruvian Partners and the other shareholders.

As part of the transaction, Benify will be combined with Zellis Group’s benefits administration and employee engagement software business, Benefex, and Vitruvian Partners will become a minority investor in the Zellis Group alongside the Apax Funds. Together, Benefex and Benify will create a leading global benefits, reward, recognition, and employee engagement software provider with an enhanced value proposition to customers globally. Completion of the transaction is subject to customary closing conditions.

Vinge’s team consisted of among others Jonas Bergström, Anna Jonsson, Nicolas Ek, Johan Severinsson and Gustav Bergengren (M&A), Nils Unckel and Anton Sjökvist (Financial Regulatory), Albert Wållgren and Arvid Weimers (Banking and Finance), Oskar Larsson (Commercial Contracts) and Emelie Svensäter Jerntorp and Carolina Lundh (Employment).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025